Cancer attack with immune cells made from iPS cells Submit clinical trial plan January 30, 4:17
RIKEN and a group at Chiba University, which are developing new therapies to attack cancer using immune cells made from iPS cells, have been working on a trial to transplant cells into real patients for national approval. The plan has been submitted to the review committee of Chiba University.
Akihiko Furuseki's team leader at RIKEN and a group at Chiba University and other groups are developing new therapies that create immune cells called NKT cells from iPS cells and administer them to patients to attack cancer.
The group has confirmed a certain effect in animal experiments, etc., and concluded that by 30 days the clinical trial plan aimed at national approval was compiled and submitted to the Chiba University review committee.
According to the plan, the target is "craniocephaly cancer" that can be applied to the tongue and throat, etc., and three tens of millions of NKT cells made from iPS cells were given to three patients who were unable to perform other treatments such as surgery. It means transplanting the individual and checking the safety and effect over 2 years.
NKT cells are originally a type of immune cell in the human body, but the number is small and it takes time to culture. Therefore, the group prepares a large amount of NKT cells from iPS cells in advance, It is expected to be applied to the treatment of cancer.
In order to conduct a clinical trial, the plan must be approved by the university's review committee, and the content must be examined by the Pharmaceuticals and Medical Devices Agency (PMDA), a PMDA. I want to start transplanting to patients around the summer.